BRIEF-Blackline announces pricing of IPO of 8.60 mln shares at $17/shr
* Says initial public offering of 8.60 million common shares priced at $17.00per share Source text for Eikon: Further company coverage:
Oct 5 Teva Pharmaceutical Industries Ltd said on Wednesday it would sell Allergan Plc's generics business in the UK and Ireland to India's Intas Pharmaceuticals Ltd for 603 million pounds ($769.37 million).
The sale was part of Teva's deal with the European Commission to get approval for the acquisition of Allergan's generics business, called Actavis Generics.
The company said it expected the sale to close in the next three months.
Teva completed the $40.5-billion acquisition of Allergan's generics business in August.
Actavis, which closed its $70.5 billion acquisition of Allergan in May 2015, had retained the Allergan name.
Greenhill & Co is Teva's financial adviser, while Rothschild & Co is advising Intas. ($1 = 0.7838 pounds) (Reporting by Akankshita Mukhopadhyay in Bengaluru; Editing by Sriraj Kalluvila)
TOKYO, Oct 28 Nissan Motor Co has decided to sell its entire stake in Japanese auto parts maker Calsonic Kansei Corp to U.S. private equity firm KKR &Co as part of a $3.8 billion takeover, the Nikkei daily reported, without citing its sources.
* Tata steel - announces equity partnership for its canadian iron ore mines, significant milestone in kalinganagar india